Category Archives: Public Policy

Latest From Public Policy

Delivering on Biotech’s Promise to Treat Anthrax, Smallpox, Ebola

Jim Greenwood

Thanks to federal biodefense programs that partner with industry to develop and stockpile medical countermeasures, each year America is better equipped to respond to potential biological, chemical, nuclear and radiological threats, BIO president and CEO Jim Greenwood says in a Roll Call op-ed published today. With recent anthrax and smallpox incidents at CDC and NIH labs,  which fortunately did not lead to any human exposure,  it’s worth taking a look at how we might respond Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

BIO Submits Comments on “Myriad” PTO Patent Guidance

Supreme Court - Phil Roeder

On July 31st, BIO, alongside a group of international bioindustry trade associations submitted comments to the United States Patent and Trademark Office regarding their March 4, 2014 Guidance on patent subject matter eligibility. Representing associations from Japan, Australia, Canada, the UK, Germany, Spain, Portugal Belgium, the Netherlands and others, the comments reflect a deep concern among the international community regarding how the PTO is interpreting the Supreme Court’s recent decisions in Mayo v. Prometheus and Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Partners for Healthy Dialogues: Letter to CMS

Partners for Health Dialogues

BIO, a member of Partners for Healthy Dialogues (P4HD), joined 25 medical societies and manufacturers in a letter to the Center for Medicare and Medicaid Services highlighting both their shared commitment to sunshine and the importance of context in the upcoming data release.  As BIO CEO Jim Greenwood said in a Q&A with P4HD: “We believe that part of CMS’s public service function in this area should be to help improve the public’s understanding of the need for Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

New Report: Innovation in Hepatitis C Treatment

CHI

Today, the California Healthcare Institute released a report on the public health impact of Hepatitis C and the potential of groundbreaking new treatments to save tens of thousands of lives over the coming decades. Innovation in Hepatitis C Treatment: New Opportunities for Action explores the incredible progress that has been made in Hepatitis C treatment in the decades since the Hepatitis C virus was identified as the cause of the disease in 1989. Early treatments Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

What International Trade Agreements Have to Do with Innovation

Attendees

Innovation is not just the life-blood of the biotech industry, it is the very premise of the BIO International Convention. So what is a panel on international trade doing here? Answering this question is the task panel moderator, Richard Bergstrom, Director General, EFPIA gave to participants in the session TTIP: Can US and the EU Lead the Way in Setting New Global Benchmarks for IP, Regulatory and Market Access Issues; and each provided a piece Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,